NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MOREPENLAB · data 2026-10-30
Morepen Laboratories Limited
In plain words
Price: 24.8% below its 52-week high of ₹150.7.
Delivery: 30.6% of traded shares were kept for delivery over the last 10 sessions, against 29.4% over the last 60.
Latest results: a net profit of ₹89 cr for the quarter ended Sept 2026 (+117.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,286 cr |
| Net profit (last 12 months) | ₹189 cr |
| Sales growth, 3 years (yearly) | 8.4% |
| Profit growth, 3 years (yearly) | 34.9% |
Latest results in brief (Q2 FY27)
MOREPENLAB Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹746.5 crore, up 81.4% YoY and up 30.9% QoQ.
Net profit was ₹88.89 crore, up 117.5% YoY and up 57.6% QoQ.
Operating margin was 16.5% (7.5% a year ago).
EPS was ₹1.62, up 116% YoY and up 57.3% QoQ.
MOREPENLAB के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹746.5 करोड़; पिछले साल की तुलना में 81.4% की बढ़त, पिछली तिमाही की तुलना में 30.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹88.89 करोड़; पिछले साल की तुलना में 117.5% की बढ़त, पिछली तिमाही की तुलना में 57.6% की बढ़त।
ऑपरेटिंग मार्जिन: 16.5% (एक साल पहले 7.5%)।
EPS: ₹1.62; पिछले साल की तुलना में 116% की बढ़त, पिछली तिमाही की तुलना में 57.3% की बढ़त।
MOREPENLABના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹746.5 કરોડ; ગયા વર્ષની સરખામણીએ 81.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 30.9% વધારો.
ચોખ્ખો નફો: ₹88.89 કરોડ; ગયા વર્ષની સરખામણીએ 117.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 57.6% વધારો.
ઓપરેટિંગ માર્જિન: 16.5% (એક વર્ષ પહેલાં 7.5%).
EPS: ₹1.62; ગયા વર્ષની સરખામણીએ 116% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 57.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹3.06 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Deal ● Results
- 18 Sept 26Dividend Dividend ₹0.2 (ex-date) +1.5% next session
- 16 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹3.06 cr +13.5% next session
- 4 Aug 26Results Q1 FY27 results: profit +424.7% YoY +33.5% next session
- 26 May 26Results Q4 FY26 results: profit −22.5% YoY -3.4% next session
- 22 May 26Results Results board meeting +1.7% next session
- 10 Feb 26Results Q3 FY26 results: profit +3.1% YoY +0.5% next session
- 14 Nov 25Results Q2 FY26 results: profit +17.3% YoY -0.7% next session
- 29 Aug 25Dividend Dividend ₹0.2 (ex-date) +2.2% next session
- 6 Aug 25Results Q1 FY26 results: profit −70.3% YoY -12.0% next session
- 12 May 25Results Q4 FY25 results: profit −28.1% YoY +6.8% next session
- 6 Feb 25Results Q3 FY25 results: profit −16.6% YoY -8.2% next session
- 11 Nov 24Results Q2 FY25 results: profit +63.9% YoY -4.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹747 cr | ₹89 cr | +117.5% | 16.5% | 1.62 |
| Jun 2026 | ₹570 cr | ₹56 cr | +424.7% | 14.5% | 1.03 |
| Mar 2026 | ₹485 cr | ₹16 cr | -22.5% | 5.0% | 0.28 |
| Dec 2025 | ₹484 cr | ₹28 cr | +3.1% | 9.6% | 0.5 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 35.65% | 35.65% | 35.65% | 35.65% |
| Foreign institutions (FII) | 3.43% | 1.46% | 1.58% | 1.62% |
| Domestic institutions (DII) | 1.71% | 1.28% | 1.25% | 1.25% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 39.16% | 43.96% | 45.15% | 45.17% |
| Number of shareholders | 4,03,932 | 4,34,912 | 4,47,286 | 4,53,137 |
Common questions
What was Morepen Laboratories Limited's latest quarterly profit?
Morepen Laboratories Limited reported a net profit of ₹89 cr for the quarter ended Sept 2026 (+117.5% on the same quarter a year earlier), on revenue of ₹747 cr.
How much do promoters hold in Morepen Laboratories Limited?
Promoters held 35.65% of Morepen Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Morepen Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Morepen Laboratories Limited's P/E ratio?
About 32.9, based on the last 12 months' earnings and a price of ₹113.35 (data 2026-10-30).
What is the 52-week high and low of Morepen Laboratories Limited?
The 52-week high is ₹150.7 and the 52-week low is ₹33.05.
Similar companies
Bliss GVS Pharma Limited (BLISSGVS) · Supriya Lifescience Limited (SUPRIYA) · FDC Ltd. (FDC) · Innova Captab Limited (INNOVACAP) · Sun Pharma Advanced Research Co. Ltd. (SPARC)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MOREPENLAB in NSE Scanner →